Statin Continuation Recommendations for Older Adults with Cardiovascular Disease

Guideline Recommendations

The American Geriatrics Society’s review of 18 international cardiovascular‑disease prevention guidelines found no specific recommendation to discontinue statins solely on the basis of age【1】【2】【3】 (Evidence level: moderate, based on systematic review).
The same society’s guidelines state that statin discontinuation should be considered only in three situations: documented statin intolerance, poor overall health status, or limited life expectancy【1】【4】 (Evidence level: expert consensus).

Limited life expectancy – Discontinuation is appropriate when a patient’s expected survival is less than one year or when the patient is enrolled in palliative‑care services【5】 (Evidence level: low‑moderate, based on a small randomized trial and expert opinion).
Advanced, life‑limiting illness with declining functional status – In such contexts, the long‑term cardiovascular benefit of statins may be outweighed by immediate quality‑of‑life concerns【5】 (Evidence level: low, expert consensus).
Statin intolerance – Documented severe adverse effects such as significant muscle pain or hepatotoxicity justify stopping the medication【1】【2】 (Evidence level: moderate, based on guideline consensus).

For a functionally independent older adult who tolerates statin therapy well, continuation is recommended because discontinuation in secondary‑prevention patients is linked to higher mortality and event rates【1】【2】【4】 (Evidence level: moderate, derived from consistent observational data).

High‑quality randomized trial data are lacking for patients aged ≥ 85 years, as this group is typically excluded from clinical trials【1】【2】【3】 (Evidence level: low).
Ongoing monitoring for adverse effects (e.g., muscle symptoms, drug‑drug interactions in polypharmacy, changes in functional or cognitive status) remains essential【5】 (Evidence level: expert recommendation).
Reassessment is advised if the patient develops multimorbidity with declining functional status, as treatment priorities may shift【1】【2】 (Evidence level: expert consensus).

Systematic review of geriatric cardiovascular guidelines (Journal of the American Geriatrics Society, 2019) found that deprescribing initiatives in older adults with cardiovascular disease have not traditionally targeted statins when patients have documented atherosclerotic disease, indicating that continuation remains the evidence‑based approach for secondary prevention. 6

The same review highlighted the risk of a prescribing cascade, whereby clinicians may add symptomatic treatments (e.g., analgesics) to manage statin‑related side effects; therefore, clinicians should verify that any additional medications are not being used to mask statin intolerance before considering discontinuation. 6

In the context of polypharmacy, the review recommended routine assessment for drug‑drug interactions when maintaining statin therapy in older adults, emphasizing that medication burden alone does not justify stopping a statin in secondary‑prevention patients. 6